Needham & Company LLC restated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a research report report published on Monday, Benzinga reports. Needham & Company LLC currently has a $2.50 price objective on the stock. Separately, Cantor Fitzgerald lowered their target price on shares of Lucid Diagnostics from $3.80 to […]
Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) is scheduled to announce its earnings results before the market opens on Monday, May 13th. Parties that are interested in registering for the company’s conference call can do so using this link. Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last posted its quarterly earnings data on Tuesday, March […]
Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.26) EPS for the quarter, Yahoo Finance reports. The business had revenue of $1.04 million for the quarter. Lucid Diagnostics had a negative net margin of 2,169.07% and a negative return on equity of 8,334.14%. During the same […]
Lucid Diagnostics (NASDAQ:LUCD) Announces Quarterly Earnings Results themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 108,700 shares, a growth of 12.4% from the October 15th total of 96,700 shares. Approximately 1.1% of the company’s shares are short sold. […]